BioAge, IPO
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement.
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 and plans to list on the Nasdaq under the symbol BIOA.
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M. Read more here/
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.
Drugmaker seeks $157.5M in IPO, placement
BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg reported Sept. 18.
Obesity drugmaker BioAge targets $158 million in IPO
The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday
Capital Markets
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
AOL16d
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 ...
Benzinga.com16d
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
The company's lead drug Azelaprag has been well-tolerated in 265 individuals across eight Phase 1 trials. The STRIDES clinical trial will assess azelaprag with Eli Lilly's Zepbound, with topline ...
Seeking Alpha15d
BioAge Labs Readies $100 Million IPO Plan For Obesity Treatment
A Quick Take On BioAge Labs, Inc. BioAge Labs, Inc. (BIOA) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The company is a clinical ...
pharmaphorum2d
Respiratory biotech Upstream joins Nasdaq IPO surge
queue amid a flurry of IPO activity in the sector, with three biotechs listing on the Nasdaq last week – Bicara ...
BioSpace16d
Lilly Partner BioAge Files for IPO to Advance Obesity Candidate
BioAge will use the proceeds from the initial public offering to move its oral apelin receptor agonist azelaprag past its ...